Gilead Sciences halts Phase II trial of GS 9450 for chronic hepatitis C
Gilead Sciences, Inc. today announced the company is stopping its ongoing Phase II clinical trial of GS 9450, an investigational caspase inhibitor, in patients with chronic hepatitis C. This decision follows reports of significant laboratory abnormalities and adverse events in a number of clinical study participants.
Leave a Response
You must be logged in to post a comment.
